section name header

Pronunciation

ox-AZ-e-pam

Classifications

Therapeutic Classification: antianxiety agents, sedative/hypnotics

Pharmacologic Classification: benzodiazepines

Indications

BEERS REMS


Action

  • Depresses the CNS, probably by potentiating GABA, an inhibitory neurotransmitter.
Therapeutic effects:
  • Decreased anxiety.
  • Diminished symptoms of alcohol withdrawal.

Pharmacokinetics

Absorption: Well absorbed following oral administration. Absorption is slower than with other benzodiazepines.

Distribution: Widely distributed. Crosses the blood-brain barrier. May cross the placenta and enter breast milk.

Metabolism/Excretion: Metabolized by the liver to inactive compounds.

Protein Binding: 97%.

Half-Life: 5–15 hr.

Time/Action Profile

(sedation)

ROUTEONSETPEAKDURATION
PO45–90 minunknown6–12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: tachycardia

Derm: rash

EENT: blurred vision

GI: constipation, diarrhea, drug-induced hepatitis, nausea, vomiting

GU: urinary problems

Hemat: leukopenia

Neuro: dizziness, drowsiness, confusion, depression, hangover, headache, impaired memory, paradoxical excitation, slurred speech

Resp: respiratory depression

Misc: physical dependence, psychological dependence, tolerance

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Serax

Contr. Subst. Schedule

Schedule IV (C-IV)